Donald P. Lehr, who serves as Chief Legal Officer at PRECIGEN, INC. (NASDAQ:PGEN), executed a sale of company shares on May 28, 2026. Specifically, Mr. Lehr sold 29,131 units of the company's common stock. This transaction generated total proceeds amounting to $127,011, with each share priced at $4.36.
The sale was explicitly categorized as a "sell-to-cover" action. Such transactions are typically executed to fulfill tax withholding obligations that arose from the vesting of restricted stock units on May 23, 2026. Following this divestiture, Mr. Lehr's direct holdings in Precigen common stock were calculated at 755,461 shares.
It is noteworthy that while PGEN stock has demonstrated a substantial return of 229% over the preceding year, some analysis from InvestingPro suggests that current share levels may be considered overvalued. Despite this valuation caution, an additional tip provided by InvestingPro indicated that analysts anticipate Precigen will achieve profitability within the current year, which could mark a significant inflection point for the biotech firm.
The recent corporate developments at Precigen Inc. provide context to these insider transactions. The company released its Q1 2026 earnings report, delivering results that surpassed market expectations. Financially, Precigen reported an earnings per share (EPS) of -$0.02. This figure was better than the forecasted EPS of -$0.03. Furthermore, revenue reached $23.25 million, exceeding the anticipated $20.8 million, pointing toward a stronger financial showing compared to analyst predictions.
In addition to these robust financial metrics, Precigen announced major regulatory milestones concerning its drug, PAPZIMEOS. The U.S. Food and Drug Administration (FDA) granted orphan drug exclusivity for PAPZIMEOS, a treatment designed for recurrent respiratory papillomatosis. This exclusivity is effective until August 14, 2032.
PAPZIMEOS itself received full FDA approval in August 2025 and is currently available nationwide through prescription. These compounding developments underscore significant progress across multiple fronts for Precigen, spanning both its financial performance and the regulatory protection afforded to its key product.
Key Takeaways from the Analysis
- Analyst caution suggests that despite strong performance, the current valuation of PGEN shares may be overvalued.
- The company is still reporting negative earnings per share for Q1 2026 (EPS of -$0.02), indicating ongoing path to profitability challenges.
- Future financial stability remains dependent on achieving sustained operational improvements and market adoption of PAPZIMEOS.